Philip Gutry

Philip Gutry is an accomplished professional in the biopharmaceutical sector, currently serving as Executive Advisor at New Mountain Capital and Chief Business Officer (Advisory) at NorthSea Therapeutics since July 2023. Gutry also holds the position of Biopharmaceutical Executive at SFA Life Sciences LLC, providing strategic advisory services in business development, financing strategies, and IPO preparations. With a robust history of leadership roles, including Chief Business Officer at Graphite Bio and Kronos Bio, Gutry has successfully led significant financing efforts, including a $150M Series B and a $273M IPO. Previous experience includes pivotal positions at Regeneron Pharmaceuticals and Gilead Sciences, where Gutry facilitated over $6B in M&A and licensing deals. Gutry holds an MBA in Healthcare Management from The Wharton School and an AB in Earth Sciences from Dartmouth College.